Aims: This project investigates whether mother and baby music sessions in the inpatient perinatal mental health setting can effectively reduce maternal anxiety, improve mood, and strengthen the mother–baby bond. It aims to review existing literature and reflect on the practical implementation of a pilot music group within a mother and baby unit (MBU).

MBUs are specialist inpatient wards which keep mothers united with their babies during treatment to maintain the mother–baby bond. Therapeutic activities vary across units, but music groups have been explored as a potential intervention to improve maternal mental health and bonding.

Methods: A literature review was conducted, identifying 8 relevant studies. The pilot music group, based on supporting literature, consisted of 6 weekly hour-long sessions, involving singing nursery rhymes and improvisation. Participants included 15 mothers with various mental health conditions. Reflections from the author/session lead and staff present were recorded to evaluate the intervention.

Results: Literature showed improvements to maternal anxiety and maternal mood after attending singing groups however the populations studied in most papers did not reflect those with more severe mental health conditions and few showed statistical significance. Bonding improvements were consistently noted across studies, often assessed through qualitative feedback or bonding scales. The pilot sessions were well-received, with mothers reporting relaxation and enjoyment. However, practical challenges emerged, not alluded to in previous literature, including cultural relevance of songs, emotional triggers, and varying levels of engagement amongst mothers with differing mental health conditions.

Conclusion: Music groups show promise as a therapeutic intervention for enhancing maternal mental health and bonding, reflected in those who attended the pilot music group. Quantitative research on its benefit in more unwell mothers admitted for treatment is still required. Challenges such as emotional triggers and the inclusion of diverse patient populations were identified in this pilot and efforts should be made to mitigate this in further interventions of a similar nature. Future research should focus on mothers with severe illness, particularly those admitted to MBUs, and explore the long-term impact of music groups as a routine intervention to support maternal–infant bonding during treatment.

Aims: Epilepsy can present with a wide range of neuropsychiatric manifestations. A seizure episode may take the form of motor convulsions, complex abnormal behaviours or unusual subjective experiences.

Seizures originating in different anatomical locations take characteristic forms, however, there is considerable overlap in the presentation.

Frontal lobe seizures are characterised by motor phenomena which may include complex posturing and behavioural automatism which tend to begin and end abruptly.

This condition is of particular importance to psychiatrists, due to the bizarre nature of automatic behaviour. They may be mistaken as dissociative phenomena or psychotic disorders.

Methods: A 55-year-old female who was previously well, presented to the psychiatric service following episodic disorganised behaviour for two weeks duration. For example, she had cooked rice three times per meal without an apparent reason. Also, she had started collecting a large number of vegetables repeatedly in a shopping centre without a clear purpose. At that time her husband had to forcefully stop her. When inquired later she was unable to recall these events. Family members also noticed that the patient is having episodic repetitive facial movements without losing consciousness.

General physical and neurological examination was normal. Her EEG showed right frontal sharp waves which progress into generalised spikes, suggestive of frontal lobe epilepsy with secondary generalisation. The contrast CT brain was normal. Haematological tests including random blood sugar, serum electrolytes, full blood count, serum calcium levels and the ECG were normal. Intravenous phenytoin sodium was given to control repetitive seizures at the onset.

Subsequently, oral sodium valproate was commenced. She responded well, and symptoms disappeared within a couple of days.

Results: Epilepsy presenting as behavioural and psychiatric manifestations is common but can be easily overlooked. Frontal lobe epilepsy with common aetiology like post traumatic, tumours and genetic causes can have complex seizure semiology.

Overall frontal lobe seizures tend to begin and end abruptly, are brief and frequent. They show a tendency to occur at night and in clusters. Motor phenomena which may include complex posturing and behavioural automatism are usually the most conspicuous feature.

This patient had several bizarre behaviours which could be complex behavioural automatism. The bizarre nature of automatism means that they can often be mistaken for non-epileptic dissociative seizures as well as another psychiatric diagnosis like mania or psychosis.

Conclusion: Our patient highlights the unusual way of presentation of frontal lobe seizures. Clinicians need to be aware of this presentation to minimise possible misdiagnosis and mismanagement.

Aims: Prosopometamorphopsia is an extremely rare phenomenon where the individual perceives facial distortions in self or others. “Demon face syndrome” and “Alice in Wonderland syndrome” are some lay terms coined to describe this condition.

Methods: We report a case of a male in his thirties, married, and a father of one, who presented to the psychiatry unit perceiving distorted facial features of self (autoprosopometamorphopsia) for eight years with exacerbation since last year. He alluded to his reflection in the mirror as the face of a demon. This resulted in significant social avoidance and rumination of other people’s perceptions of his appearance. At the time of presentation, he was having a severe depressive episode with significant occupational and functional decline and was consuming excessive alcohol as a maladaptive coping strategy.

When the symptom first appeared eight years ago while working in the military, he perceived similar distortions in a co-officer’s face in addition to his face, which culminated in him resigning from the forces due to the distress. He did not seek medical treatment, and symptoms went into spontaneous remission after a few months. He was satisfactorily functioning until a year ago.

Apart from prosopometamorphopsia, he did not have any other psychotic symptoms or symptoms suggestive of manic episodes. He was diagnosed with anti-NMDA encephalitis one year ago and had suffered seizures. He reportedly lost the neuroimaging and treatment records related to this episode.

Results: The patient was initially diagnosed of Body Dysmorphic Disorder (BDD) and had been treated with adequate trials of antidepressants with very poor response. Due to the severity of depression, functional decline and previous poor response to antidepressants, he was treated with electroconvulsive therapy (ECT) during his current admission. During the one-month post-discharge evaluation, he showed satisfactory improvement and was continued on imipramine 150 mg and olanzapine 20 mg in the night. He was also on topiramate 50 mg nocte from the neurology clinic.

Conclusion: Existing literature reveals that prosopometamorphopsia has an organic basis with malfunctioning brain facial recognition systems playing a critical role in its manifestation. In this patient, a history of NMDA encephalitis suggests neuropsychiatric aetiology. Lack of response to conventional treatment for BDD and good response to ECT indicates that this condition is a different entity warranting tailored treatment.

Aims: With this systematic review, an attempt will be made to systematically compare the efficacy and side effects of Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) in Chronic Pain Conditions in terms of functional improvement and quality of life with placebo.

Methods: The relevant studies were included after conducting a literature search in OVID, PubMed/MEDLINE, EMBASE/SIGLE, CINAHL, and Web of Science. Randomized controlled trials that compared SNRIs in chronic pain were included in the review. In the assessment of study quality, the Cochrane Risk-of-Bias tool was used. A number of data extractors and analysts were used in the study so as to reduce possible bias in the study results.

Results: Duloxetine appeared to be the SNRI with the best therapeutic efficacy profile across different chronic pain types and aetiologies such as osteoarthritis, fibromyalgia, and chronic low back pain. It showed reasonable effectiveness in alleviating pain magnitude and enhancing motor activity. The results were consistent between standard and higher doses of single administration 60 mg. Duloxetine demonstrated a significant reduction in pain when compared with placebo. An improvement in functional status and quality of life measured through self-reported scales was also noted. This trend was more pronounced in the treatment of the patients on SNRI compared with those on placebo.

Conclusion: Duloxetine appears to be effective for chronic pain conditions and may help reduce pain intensity, increase functional status and improve the quality of life. Even though rigorous trials indicate that these drugs are superior to placebo after 8–16 weeks, long-term effect and safety profiles are not very clear, and more long-term studies are needed to understand the durability and application of the drugs in clinical practices. Further research should prospectively investigate the efficacy in long-term pain, different comorbid conditions, and include predictors of SNRI response.

Aims: This study through systematic review approaches and meta-analysis aimed to determine safe drug options for treating male sexual dysfunction due to erectile dysfunction by comparing sildenafil, tadalafil, vardenafil, mirodenafil, coenzyme Q and testosterone.

Methods: Systematic review methodology was used to retrieve data from complete database searches done in PubMed/MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Randomized controlled trials research designs with adult male participants who presented with erectile dysfunction on sildenafil, tadalafil, vardenafil, mirodenafil, coenzyme Q and testosterone were included as part of the review. The Cochrane Risk of Bias version 2.0 was utilized by two independent reviewers for assessing bias risk and extracting data. Sensitivity analysis was used to reduce the risk of bias.

Results: Phosphodiesterase inhibitors type 5 (PDE 5) are the most effective medications for erectile dysfunction (ED). Participants on sildenafil had effective erections between 77–84% at doses of 50–100 mg and tadalafil emerged as the “Weekend pill” because of its 36-hour maximum effect duration of action. The concentration-focused activity along with higher potency values of vardenafil make it superior to other PDE5 inhibitors. The newly developed therapeutic medication mirodenafil exhibits better PDE5 selectivity than existing drugs within its operational mechanism. Minor variations were noted as a cohort of participants preferred tadalafil above sildenafil. Testosterone supplementation is beneficial for when monotherapy with a PDE5 inhibitor has not been effective.

Conclusion: Being the first-line treatment for erectile dysfunction, PDE5 inhibitors should be prescribed based on the distinctive pharmacological attributes they possess. Medical treatment selection methods must take into account both the need of patients as well as their preference. The recent introduction of mirodenafil medication has opened new possibilities in the medical treatment of ED. The effectiveness of ED treatment brings optimistic outcomes to the quality of life to hundreds of millions of men across the globe and further studies will drive medical progress to improved treatment modalities including stem cell therapy.

Aims: Ketamine and behavioural activation (BA) reduce levels of anhedonia in major depressive disorder (MDD), though neither resolves anhedonia. Combining these treatments could yield additive or even multiplicative benefits.

This poster summarises the development of a PhD fellowship proposal, discussing: (1) the initial patient and public involvement (PPI) interviews, exploring views on participation in ketamine research; (2) the resulting proposal, assessing the feasibility of a trial augmenting BA with IV ketamine for MDD and anhedonia.

Methods: 1. One-to-one PPI interviews were conducted with seven participants from a previous study of ketamine in treatment-resistant depression. Questions addressed (a) volunteering reasons, (b) positives to retain and areas to improve and (c) research objectives opinions.

2. Participants with MDD and anhedonia will be recruited from the community and local primary care services (GP and NHS Talking Therapies). A planned feasibility parallel-group randomised controlled trial will compare IV ketamine with BA (n=20), against midazolam with BA (n=20). Participants will attend eight visits (including one-month follow-up) over 10–12 weeks, receiving 3 ketamine or midazolam infusions in between 6 BA sessions. Feasibility of study procedures and collection of outcome measures will be assessed.

Results: A key motivator for participants to volunteer was hope that ketamine would improve depression symptoms. Some were curious about ketamine’s effects. They wished to support research into depression treatments.

Most participants experienced a stark difference between ketamine and midazolam (placebo). They described feeling more open, malleable and involved in the world after ketamine.

Participants suggested future studies retain a focus on treating participants as individuals rather than a ‘number’ and allowing unrushed sessions. They thought clinician-led interviews helped reflect on symptom changes.

Participants found the consent process thorough. However, some suggested it should be clearer that mood changes from ketamine may not last. They recommended providing audiovisual materials on the ketamine experience/infusion room to support preparation. They suggested a check-in between infusion sessions and a final session to discuss onward referrals, medication advice and signposting to low-cost counselling and integration groups.

Most thought ketamine could enable better use of therapy time and that therapy could help make sense of thinking changes post-ketamine. Other suggestions for research included duration of symptom relief post-ketamine, treatment accessibility including in primary care, and medication side effects.

Conclusion: PPI interviews supported combining ketamine with psychotherapy. They provided key insights on improving study procedures to support research into augmenting primary care therapies for depression treatment.

Aims: The global demographic transition has led to a growing ageing population. Neurodegenerative disease prevalence is high in the elderly, as aged brains accumulate molecular and cellular damage. Protein misfolding and aggregation are pathological processes underlying neurodegeneration, as seen in dementia. This coupled with oxidative stress, disrupted ubiquitin-proteosome system and neuroinflammation may contribute to neuronal damage/death. Lewy Body dementia (LBD) collectively refers to Parkinson’s disease (PD), Parkinson-disease dementia and dementia with Lewy bodies (DLB). It is characterised by Lewy Body (LB) deposits in the central nervous system, predominantly compromised of misfolded α-synuclein protein. Disease-modifying therapy (DMT) targets underlying protein misfolding and promotes LB clearance.

To review international trials on DMT safety, tolerability and efficacy in DLB.

To consider the molecular basis for protein misfolding and DMT in DLB.

Methods: Two international registries (ClinicalTrials.gov; EU clinical trials register) were consulted to identify agents being tested in completed, ongoing and recruiting trials. Both databases were searched by disease “Lewy body dementia” or “LBD” or “alpha-synuclein pathology” and study type “interventional” for phase I–III trials. Trials solely investigating diagnostic biomarkers, approved symptomatic DLB treatment or PD without dementia symptoms were excluded from final analysis.

Results: 11 trials were found studying DMTs for DLB. 10 out of the 11 trials were in phase II and one in phase I. The main agents investigated were tyrosine-kinase inhibitors (TKIs), phosphodiesterase-9 inhibitors, β-adrenergic agonists, and β GCase chaperones. Primary and secondary outcome measures were “safety/tolerability of agent”, “changes in cognitive function” or “changes in serum/CSF α synuclein levels”. Results from a phase I trial demonstrated a 3.85 and 3.5-point increase in mini-mental state examination scores at 6 months with nilotinib doses 300 mg and 150 mg, respectively. Contrastingly, only slight reduction in CSF/plasma α-synuclein was observed. Phase II trials for bosutinib versus placebo showed no significant difference in cognitive function. Trials for ambroxol, a β-GCase enzyme enhancing inhibitory chaperone, remain in recruiting stages but have proven drug tolerability due to fewer side effects. Data on CSF biomarker changes in DLB was unavailable.

Conclusion: Current understanding of protein misfolding in α-synucleinopathies suggests that a single DMT may be insufficient in mixed pathology. Cocktail therapy targeting various misfolded proteins may be necessary for a cure. DMTs have limited use as most patients are diagnosed with advanced DLB. Sensitive diagnostic biomarkers with high specificity are required for accurate DLB diagnosis in the prodromal phase, a critical window for protein misfolding reversal with DMT.

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide are considered breakthrough drugs in the management of diabetes and obesity. Beyond their metabolic benefits, these pharmacological agents interact with biological pathways that may influence brain function, and are therefore increasingly being investigated for possible repurposing in psychiatric and neurological disorders. This review aims to synthesise pre-clinical and clinical evidence on the effects of GLP-1RAs across a range of cognitive and mental health conditions, comprehensively assessing their therapeutic potential and translational implications for psychiatric practice.

Methods: A systematic literature search was conducted across multiple databases, using a broad search algorithm to maximise the scope of the evidence synthesis. Two researchers independently screened titles and abstracts, assessed full texts for eligibility, and extracted relevant data. Results were considered in a narrative and visual synthesis based on emerging categories: studies were divided into mechanistic and clinical evidence, and organised based on broad diagnostic domains (cognitive disorders, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders). Clinical evidence, including meta-analyses, randomised controlled trials (RCTs), and observational studies, was critically appraised and ranked by hierarchy of evidence.

Results: The main themes emerging from the 280 pre-clinical and 96 clinical studies identified consist of the potential benefits of GLP-1RAs in neurocognitive disorders (reducing dementia risk and cognitive impairment in various cohorts) and in substance use disorders. Mechanistic evidence suggests these are mediated through their multimodal neuroprotective effects (including via anti-inflammatory pathways) and by dopaminergic modulation of reward mechanisms, respectively. In psychotic disorders, GLP-1RAs primarily mitigate antipsychotic-induced metabolic side effects, with minimal evidence for direct effects on psychosis itself. Findings in mood and anxiety disorders are inconclusive, with some studies reporting antidepressant properties while others show no clear benefit. Evidence in eating disorders is scarce, but suggests GLP-1RAs may influence binge-eating behaviour, aligning with pre-clinical findings on their influence on appetite and reward regulation.

Conclusion: Extensive pre-clinical literature on GLP-1RAs provides strong mechanistic support for their putative benefits in Psychiatry, particularly in cognitive and reward-related disorders. However, clinical studies have yet to fully confirm these effects, highlighting the need for high-quality, targeted trials to distinguish direct mental health effects from secondary metabolic improvements. As enthusiasm about the promise of GLP-1RAs continues to grow in both the scientific community and in the media, it is crucial to approach their adoption in Psychiatry cautiously, and focus on robust translational research to establish their long-term efficacy and safety in patients with mental health conditions.

Aims: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that primarily affects motor function but also impairs cognitive and emotional regulation. Dopaminergic therapy, commonly used to treat motor symptoms, can lead to complications such as impulse control disorders (ICDs), compulsive behaviours, and dopamine dysregulation syndrome (DDS). These complications often result in significant deterioration of patients’ quality of life. This dissertation aims to investigate effective interventions for managing ICDs and compulsive behaviours in PD patients on dopaminergic treatment while minimizing the risks of motor symptom deterioration and other neuropsychiatric consequences.

Methods: This systemic literature review examines a wide range of interventions for managing ICDs and compulsive behaviours in PD patients. A comprehensive search was conducted across major medical and psychological databases to identify studies evaluating pharmacological and non-pharmacological treatments. The review focused on interventions such as clonidine, atomoxetine, cognitive behavioural therapy (CBT), and subthalamic nucleus deep brain stimulation (DBS). Inclusion criteria were studies published in peer-reviewed journals within the last two decades that specifically addressed the treatment of ICDs and compulsive behaviours in PD patients receiving dopaminergic therapy.

Results: The review found that several interventions show promise in managing ICDs and compulsive behaviours without exacerbating motor symptoms. Clonidine and atomoxetine, both of which affect norepinephrine pathways, have been identified as potentially effective pharmacological options for controlling impulsivity and compulsive behaviours. CBT has been highlighted as an effective psychological intervention, particularly in improving patients’ coping mechanisms and reducing maladaptive behaviours. Additionally, deep brain stimulation of the subthalamic nucleus has demonstrated positive effects on reducing impulsivity in PD patients, though its use remains primarily for motor symptom management. However, the evidence remains inconclusive regarding the optimal approach for balancing treatment of both motor and non-motor symptoms.

Conclusion: The management of ICDs and compulsive behaviours in PD patients remains complex due to the delicate balance between controlling motor symptoms and minimizing dopaminergic side effects. While pharmacological interventions such as clonidine and atomoxetine, as well as non-pharmacological treatments like CBT and DBS, offer potential benefits, further research is needed to refine these approaches. Additionally, more tools are required for the comprehensive risk assessment of ICDs and compulsive behaviours to guide clinicians in tailoring treatments that safeguard both motor function and mental well-being, ultimately improving patient quality of life.

Aims: Memantine, an N-methyl-D-aspartate receptor antagonist, is primarily approved for the treatment of Alzheimer’s disease and other forms of dementia. However, multiple studies have explored its potential applications in psychiatric disorders. This literature review aims to evaluate existing evidence on the efficacy of memantine in conditions such as trichotillomania, skin picking disorder, depression, bipolar disorder, obsessive-compulsive disorder, ADHD, autism spectrum disorder, substance use disorder, schizophrenia, and reducing cognitive effects of electroconvulsive therapy. The review hypothesizes that, based on available literature, memantine may have therapeutic potential across these psychiatric disorders, particularly as an adjunct treatment.

Methods: A literature search was conducted using PubMed from 2020 to 2025 (5 years), employing the search strategy ((Memantine) AND (Psychiatry)) NOT (Dementia). This literature review was conducted by screening 27 searched titles. The inclusion criteria encompassed systematic reviews, meta-analysis and randomised controlled trials. Exclusion criteria included animal and cell studies, case studies, reviews, editorials, case reports, and letters to editors. A total of 23 papers were included in this review and 4 were excluded as they focused on conditions outside the scope of this review.

Results: Emerging evidence from the 23 selected studies (9 RCTs, 8 systematic reviews, 2 meta-analyses, and 4 combined systematic reviews with meta-analyses) suggests that memantine may be beneficial across various psychiatric disorders, particularly as an adjunct. Most of the available literature points towards a positive response of using memantine in conditions like trichotillomania, skin picking disorder, depression, bipolar disorder, obsessive-compulsive disorder, ADHD, autism spectrum disorder, substance use disorder, schizophrenia, mitigating cognitive effects of electroconvulsive therapy, and other conditions. However, the number of studies per disorder that met the inclusion criteria was limited. This highlights the lack of extensive research for individual disorders and the need for further clinical validation.

Conclusion: Memantine’s NMDA receptor antagonism offers a promising yet underexplored therapeutic approach in psychiatry. While preliminary findings suggest potential benefits across multiple psychiatric disorders, the number of high-quality studies per condition remains very limited, with most disorders represented by only three or four studies meeting the inclusion criteria. This underscores the need for more randomized controlled trials with larger sample sizes to validate its efficacy, refine dosing strategies, and assess long-term safety. Expanding research in this area is crucial to clarify memantine’s role in psychiatric practice and prevent its underutilization.

Aims: The menopausal transition, marked by a sharp decline in oestrogen, is increasingly recognised as a critical period for new onset of psychosis or worsening symptoms in women with pre-existing schizophrenia, yet treatment strategies remain largely overlooked. Oestrogen’s profound neuroprotective effects – modulating dopaminergic, serotonergic, and glutamatergic pathways, and mediating neural apoptosis – suggest that hormone-based therapies could revolutionize the management of menopause-associated psychosis (MAP) and exacerbation of pre-existing schizophrenia in peri- and post-menopausal women. However, concerns over the long-term risks of hormone replacement therapy (HRT), including breast and uterine cancer and cardiovascular disease, have hindered its widespread adoption. In contrast, the emergence of selective oestrogen receptor modulators (SERMs) have offered a novel, safer alternative with a potentially broader therapeutic window. This review synthesises the current evidence, explores the differential efficacy of hormone therapies including HRT and SERMs, compares response between the above populations of peri- and post-menopausal women with psychosis, and identifies gaps in the literature that warrant further investigation. To our knowledge, this is the first literature review specifically comparing efficacy of HRT vs SERMs in the peri- and post-menopausal population of women with psychosis.

Methods: To address the questions posed about (1) efficacy of SERMs vs HRT in (2) menopause-associated psychosis vs menopausal women with pre-existing schizophrenia, the authors searched PubMed databases from years 1990 to 2025, with various combinations of the following terms: schizophrenia, late-onset schizophrenia, psychosis, late-onset psychosis, menopause, perimenopause, postmenopause, menopause-associated psychosis, oestrogen, estradiol, raloxifene, HRT, and SERMs. Over 743 relevant abstracts were found, and narrowed down to 72 reviews and experimental studies to be included in this review. Studies were selected based on their applicability to answer the authors’ questions.

Results: This comprehensive review reveals that both HRT and SERMs significantly alleviate not only psychotic but also cognitive and negative symptoms, with SERMs demonstrating superior long-term safety and sustained efficacy, as well as a longer therapeutic window of action. Crucially, differences in treatment response between menopause-associated psychosis and pre-existing schizophrenia suggest that hormonal interventions must be tailored to their underlying pathophysiological mechanisms.

Conclusion: These findings challenge the current paradigm of psychosis treatment in menopausal women and underscore the urgent need for large-scale, longitudinal studies to refine dosing strategies, assess long-term psychiatric and cognitive outcomes, and explore potential synergies between hormonal and antipsychotic therapies. Expanding research in this area could redefine psychiatric care for midlife women, offering more personalised and effective treatment pathways.

Aims: Recent research has focused on the inflammatory cascade as a key culprit in the aetiology of Bipolar disorder. We hypothesized that celecoxib, via its anti-inflammatory properties, may have a therapeutic role in mood disorder. The present study was a 4 weeks, open label case-control trial of celecoxib in patients of Bipolar mania as an adjunctive therapy to mood stabilizer and antipsychotic and to see its effect on IL-6 levels to objectively validate the improvement caused by celecoxib using this inflammatory marker.

Methods: This was a hospital-based, prospective, case-control study using purposive sampling. The study consisted of 50 participants of over 18 years of age, of which 25 received celecoxib (200 mg/day) adjunctive therapy to sodium valproate and a second generation antipsychotic while the other 25 received treatment as usual for 4 weeks. 25 healthy controls were also taken to measure and compare baseline serum Interleukin 6 levels. The Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression – Severity scale (CGI-S) were used to assess severity of symptoms at baseline and at 4 weeks. The serum Interleukin 6 level was measured at baseline and at 4 weeks using an ELISA kit.

Results: The patients in each of the groups were comparable with respect to the socio-demographic, clinical characteristics and laboratory parameters at baseline. Interleukin 6 levels in the patient groups were significantly elevated when compared with healthy controls. Repeated measures ANOVA showed significant effect on treatment × time interaction on YMRS [F (1, 48) = 104.69, p<0.001] BPRS [F (1, 48) = 9.298, p = 0.004] and CGI-S [F(1, 48) = 65.774, p<0.0001] scores. YMRS, BPRS and CGI-S scores significantly decreased at 4 weeks in Bipolar patients receiving celecoxib in comparison to Bipolar patients receiving treatment as usual. There was a significant decrease in the serum Interleukin 6 (p<0.001) while on treatment with celecoxib adjunctive when compared with treatment as usual. The baseline Interleukin 6 levels correlated significantly with the improvement in symptoms (p<0.009) and the baseline score on YMRS scale was a predictor of the improvement.

Conclusion: This study found that celecoxib used as an adjunctive therapy with sodium valproate and antipsychotic in the treatment of Bipolar mania shows improvement in the manic and psychotic symptoms. It also significantly lowers Interleukin 6 levels of participants which were raised when compared with the healthy controls.

Aims: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray in Korea. This study is aimed to evaluate the acute safety and efficacy of intranasal esketamine in patients with TRD from a university hospital in Korea.

Methods: This open-label and prospective study used data collected from the Wonkwang University Hospital. Patients with TRD received esketamine plus an oral antidepressant during the treatment period. This study comprised a 4-week screening, 2-week induction and 2-week follow-up.

Results: A total of 22 TRD patients received esketamine April 2021–April 2023. This group was predominantly female, and have several psychiatric comorbidities and high exposure to psychiatric medications. We observed significant reductions (p<0.001) in average Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impression severity (CGI-S) from baseline (HAM-D: 25.6+5.3, CGI-S: 5.1+1.5) to last available treatment(HAM-D: 19.6+3.9, CGI-S: 3.0+1.2). Suicidal thought also significantly reduced from baseline(2.33+0.7) to last treatment (1.37+0.6)(p<0.001).

Compared with the baseline, 23% of HAM-D, 43% of CGI-S and 42% of suicidal thought of TRD patients reduced in the 4 weeks. There were no reports of serious adverse events.

Conclusion: The acute safety and efficacy of esketamine in the Korean patients was generally consistent with the international studies. There was no new safety signal and no indication for abuse. Acute efficacy occurred early during the induction phase.

Aims: Medicine-taking is a complex human behaviour. Psychiatry is returning to the Bio-Psycho-Social paradigm with a re-emphasis on the relational aspects of prescribing. To improve knowledge/understanding of the key concepts of Relational Prescribing, three one-hour seminars each one week apart were delivered to clinicians at Leicestershire Partnership NHS Trust (September 2022). The overall aim was to understand the views of psychiatry trainees.

Methods: Seminars, delivered by a Senior Psychiatric Pharmacist and a Consultant Psychiatrist in Psychotherapy, included evidence and core concepts of relational prescribing.

Quantitative data was collected by pre- and post-seminar surveys consisting of Likert style questions. Ordinal analysis was applied, and findings reported as descriptive statistics.

A scoping activity consisting of an online group discussion using a semi-structured topic guide was used to collect qualitative data to get a more in-depth understanding. This was recorded, transcribed verbatim, anonymised and analysed using Framework Analysis (a type of Thematic Analysis) – chosen because it emphasises both a priori issues and themes identified.

Results: Forty-seven participants completed a pre-seminar survey, thirteen returning both pre- and post.

Six participants joined the online discussion (March 2023, lasting one hour and fifty-five minutes). Four themes were identified.

Clinician factors. Professional identity as “the prescriber”, the clinician’s conceptualisation of medication-as-object, and experience and confidence of the clinician.

Patient factors. The patient’s expectations and the patient’s experience of, and meaning attached to, medication.

Consultation factors. “Gentle dialogue” and the doctor-as-the-drug, and consultation dynamics.

Context factors. Clinical setting, brevity of appointments, lack of continuity, and service dynamics.

Conclusion: Quantitative data indicated increased confidence in Relational Prescribing (although not statistically significant). Trainees felt the most confident exploring experiences of and attitudes towards medication-taking, with less confidence in psychoeducation and patient ambivalence. Prescribing is a relational exchange involving action. Action provides relief for both parties, meeting the patient’s expectations for a concrete response to their distress and the clinician’s expectation of a powerful and impactful professional identity. Prescribing was often felt the only way to hold the anxiety. Internal and external pressures to prescribe were considered. Clinicians described the multi-layered meaning of a prescription, from the offer of an apology to an exertion of power. Clinicians felt trapped by lack of seniority and confidence. The rotational nature of training, brevity of appointments, and lack of continuity of care were felt to hinder a relational approach. The phrase “gentle dialogue” emerged de novo suggesting that non-pharmacological interventions may be felt less valid.